ARTICLE | Product Development
Argenx’s first-mover advantage in myasthenia gravis
Belgian biotech is applying lessons of past orphan drugs to Vyvgart’s launch
October 27, 2022 7:14 PM UTC
With all the makings of a stellar launch for Vyvgart, argenx is pouring capital into a marketing campaign to drive broad adoption of the therapy, aiming to leverage its first-mover advantage in what will become an increasingly competitive myasthenia gravis space.
Approved in December 2021, Vyvgart efgartigimod alfa-fcab is off to a strong start. Argenx SE (Euronext:ARGX; NASDAQ:ARGX) reported $131 million in 3Q22 sales for the first-in-class FCRN antagonist on Thursday, a 75% increase quarter-over-quarter. ...